Abstract Number: 1287 • ACR Convergence 2025
A clear pattern of clinical presentation in juvenile systemic scleroderma is associated with interstitial lung disease
Background/Purpose: Juvenile systemic sclerosis(jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. In adult systemic sclerosis is interstitial lung…Abstract Number: 0844 • ACR Convergence 2025
Machine Learning Model Incorporating Baseline and Early Follow-up Clinical Data Predicts 52-Week Cutaneous Outcomes in Systemic Sclerosis
Background/Purpose: As treatment options for diffuse cutaneous systemic sclerosis (dcSSc) expand, the need for data-driven, efficient approaches to therapeutic switching is becoming more urgent. Additionally,…Abstract Number: 1855 • ACR Convergence 2025
Small Bowel Microbial Dysbiosis and Impaired Intestinal Absorptive Function in Systemic Sclerosis- A Single Center Prospective Study
Background/Purpose: Systemic sclerosis (SSc) is characterized by peripheral vasculopathy and widespread fibrosis of skin and internal organs. Up to 90% of SSc patients report gastrointestinal…Abstract Number: 1288 • ACR Convergence 2025
Is gastroesophageal reflux a risk for interstitial lung disease in Juvenile systemic sclerosis?
Background/Purpose: Gastroesophageal involvement, particularly reflux, has been identified as a risk factor for development and progression of interstitial lung disease (ILD) in adult systemic sclerosis…Abstract Number: 0823 • ACR Convergence 2025
Longitudinal model of paired peripheral blood CITE-seq and skin scRNA-seq data in juvenile systemic sclerosis (jSSc) patients following autologous stem cell transplant (ASCT) reveals reduced expression of SSc marker genes
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a rare, life-threatening autoimmune disease characterized by fibrosis and immune dysregulation. Autologous stem cell transplant (ASCT) is an emerging…Abstract Number: L01 • ACR Convergence 2024
Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases
Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…Abstract Number: 1320 • ACR Convergence 2024
Acceptability and Satisfaction of an Online Resilience-Building Intervention with Peer Health Coaches for Managing Fatigue and Well-Being in Systemic Sclerosis
Background/Purpose: Non-pharmacological fatigue management interventions in systemic sclerosis (SSc) are limited, despite people with SSc reporting that fatigue is inadequately addressed with clinical care. We…Abstract Number: 2448 • ACR Convergence 2024
Content Validity and Sensitivity to Change of ScleroID Through the Natural History of Scleroderma. a Validated Tool to Measure the Impact of SSc on How Patients Feel and Function
Background/Purpose: Multiple patient-reported outcomes (PROs) have been utilized to capture the burden of Systemic Sclerosis (SSc), including the Health Assessment Questionnaire Disability Index (HAQ-DI), Cochin…Abstract Number: 1537 • ACR Convergence 2024
Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases
Background/Purpose: Cyclic GMP-AMP synthase (cGAS) is a nucleic acid sensor that plays a central role in anti-viral responses. Following the detection of intracellular double-stranded DNA,…Abstract Number: 2449 • ACR Convergence 2024
Acid Reflux Triggers Type I Interferon and Persistent Epithelial-mesenchymal Transition in Esophageal Epithelial Cells. a Novel Microenvironment Contribution to the Pathogenesis of Systemic Sclerosis
Background/Purpose: Gastroesophageal reflux disease (GERD) is a very common manifestation of scleroderma (SSc), affecting as high as 90% of patients, second only to Raynaud’s phenomenon.…Abstract Number: 1562 • ACR Convergence 2024
Autoantibody Associations with Disease Manifestations in Patients with Early Diffuse Cutaneous Systemic Sclerosis: The Prospective Registry of Early Systemic Sclerosis
Background/Purpose: Several autoantibodies have been linked to various disease manifestations of systemic sclerosis (SSc). Anti-RNA polymerase 3 (ARA) and anti-topoisomerase-I (ATA) are both associated with…Abstract Number: 2452 • ACR Convergence 2024
Multimodal Ultrasound in the Assessment of Sarcopenia-related Muscle Involvement in Patients with Systemic Sclerosis: A Multicentric Study
Background/Purpose: Patients with systemic sclerosis (SSc) are at an increased risk of sarcopenia and muscle involvement. This study aims to describe the ultrasound findings of…Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…Abstract Number: 1565 • ACR Convergence 2024
Prevalence and Risk Factors of Lower Extremities Arterial Disease in Systemic Sclerosis: Preliminary Data from a Single Centre Multidisciplinary Study
Background/Purpose: Microvascular changes represent a key step of pathogenic process in Systemic Sclerosis (SSc). However, SSc has been demonstrated to carry an increased risk of…Abstract Number: 2455 • ACR Convergence 2024
Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT)
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is a systemic autoimmune disease characterized by vasculopathy and multiorgan fibrosis leading to significant morbidity and early mortality. Autologous stem…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 16
- Next Page »